OverviewSuggest Edit

Twist Bioscience is a synthetic biology company that develops a proprietary silicon-based manufacturing process for the production of synthetic DNA. It manufactures a range of synthetic DNA-based products, including synthetic genes, tools for next generation sample preparation, as well as antibody libraries for drug discovery and development. Additionally, the company focuses on discovery partnerships for biologic drugs, and new applications for synthetic DNA, such as digital data storage. Twist Bioscience serves the medicine, agriculture, industrial chemicals, and data storage markets.

TypePublic
HQSouth San Francisco, CA, US
Websitetwistbioscience.com
Employee Ratings4.3
Overall CultureA+

Latest Updates

Employees (est.) (Sept 2020)525(+27%)
Job Openings56
Revenue (FY, 2020)$90.1 M(+66%)
Share Price (Sept 2021)$111(-2%)
Cybersecurity ratingBMore

Key People/Management at Twist Bioscience

Emily Leproust

Emily Leproust

CEO and Co-Founder, Board Member
Jim Thorburn

Jim Thorburn

Chief Financial Officer
Patrick Weiss

Patrick Weiss

Chief Operating Officer
Patrick Finn

Patrick Finn

Chief Commercial Officer
Aaron Sato

Aaron Sato

Chief Scientific Officer
Siyuan Chen

Siyuan Chen

Chief Technology Officer
Show more

Twist Bioscience Office Locations

Twist Bioscience has offices in South San Francisco, Carlsbad, San Francisco, Guangzhou Shi and in 2 other locations
South San Francisco, CA, US (HQ)
681 Gateway Blvd
Carlsbad, CA, US
5600 Avenida Encinas Suite 140D-2
San Francisco, CA, US
500 Terry A Francois Blvd, San Francisco
Guangzhou Shi, CN
Guanzhou Life Science Innovation Center North Tower, Second Floor, Room 203
Tel Aviv-Yafo, IL
Rothschild Blvd 3
Singapore, SG
3 Fusionopolis Pl
Show all (6)

Twist Bioscience Financials and Metrics

Twist Bioscience Revenue

Embed Graph
View revenue for all periods
Twist Bioscience's revenue was reported to be $90.1 m in FY, 2020
USD

Revenue (Q2, 2021)

31.2m

Gross profit (Q2, 2021)

12.2m

Gross profit margin (Q2, 2021), %

39%

Net income (Q2, 2021)

(37.9m)

EBIT (Q2, 2021)

(38.0m)

Market capitalization (8-Sept-2021)

5.4b

Closing stock price (8-Sept-2021)

111.0

Cash (31-Mar-2021)

399.3m

EV

5.1b
Twist Bioscience's current market capitalization is $5.4 b.
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Revenue

2.3m10.8m54.4m90.1m

Revenue growth, %

375%

Cost of goods sold

9.4m24.0m47.4m61.4m

Gross profit

(7.2m)(13.3m)7.0m28.7m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

1.7m2.4m3.2m4.3m6.2m6.5m11.5m13.6m13.6m17.2m19.3m21.2m28.2m31.2m

Cost of goods sold

5.0m6.0m6.2m7.5m8.1m7.5m11.9m11.8m11.4m13.8m13.6m16.5m18.2m19.0m

Gross profit

(3.3m)(3.6m)(3.0m)(3.2m)(1.9m)(962.0k)(365.0k)1.8m2.2m3.4m5.7m4.7m10.0m12.2m

Gross profit Margin, %

(195%)(146%)(96%)(74%)(31%)(15%)(3%)13%16%20%30%22%36%39%
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Cash

28.6m31.2m46.7m93.7m

Accounts Receivable

723.0k2.3m12.1m26.4m

Prepaid Expenses

1.2m1.5m2.6m6.2m

Inventories

1.2m1.8m7.3m12.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

66.5m28.7m68.2m26.0m184.4m207.9m348.8m399.3m

Accounts Receivable

7.0m8.0m11.7m13.1m14.8m13.3m25.5m27.3m

Prepaid Expenses

4.0m4.2m3.6m5.7m4.5m6.3m8.2m9.2m

Inventories

5.6m4.4m5.5m7.4m10.8m13.2m13.4m15.8m
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(44.1m)(59.3m)(107.7m)(139.9m)

Depreciation and Amortization

4.2m5.0m6.1m6.7m

Inventories

(1.2m)(599.0k)(1.3m)(5.0m)

Accounts Payable

466.0k560.0k3.3m(5.5m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(22.6m)(48.6m)(76.5m)(55.6m)(87.4m)(115.6m)(32.9m)(70.8m)

Depreciation and Amortization

1.5m3.0m4.6m1.5m3.1m4.8m2.1m4.6m

Inventories

467.0k1.6m532.0k(86.0k)(3.4m)(5.8m)(1.1m)(3.5m)

Accounts Payable

(715.0k)(2.0m)(96.0k)(556.0k)(3.1m)(3.8m)3.5m3.8m
USDFY, 2016

Financial Leverage

-1 x
Show all financial metrics

Twist Bioscience Operating Metrics

Twist Bioscience's Customers was reported to be 539 in Q3, 2018.
Q3, 2016Q4, 2016Q1, 2017Q2, 2017Q3, 2017Q4, 2017Q1, 2018Q2, 2018Q3, 2018

Customers

539

Order Volume

$753 k$2.31 m$2.73 m$4.21 m$4.43 m$6.19 m$7.39 m$8.52 m$10.67 m

Shipments

7519641.25 k1.69 k
Show all operating metrics

Twist Bioscience Revenue Breakdown

Embed Graph

Twist Bioscience revenue breakdown by business segment: 75.4% from Synthetic genes, 19.1% from Oligo pools and 5.5% from Other

Twist Bioscience revenue breakdown by geographic segment: 76.6% from United States, 18.8% from EMEA and 4.7% from Other

Twist Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Twist Bioscience Online and Social Media Presence

Embed Graph

Twist Bioscience Company Culture

  • Overall Culture

    A+

    85/100

  • CEO Rating

    A+

    95/100

  • Compensation

    B-

    72/100

Learn more on Comparably

Twist Bioscience News and Updates

SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies

BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offeri…

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products

VICTORIA, BC, Oct. 27, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary, Talem Therapeutics, entered into a...

DNA synthesis provider Twist Bioscience attracts $27 mln

San Francisco-based Twist Bioscience, a provider of DNA synthesis, has raised $27 million in funding. The investors were Biomatics Capital, Reinet Fund S.C.A., F.I.S., NFT Investment Limited, KANGMEI Group, Bay City Capital GF Xinde Life Science Investment Fund, 3W Partners Capital and Ditch Plains …

Twist Bioscience Blogs

Twist Bioscience Continues Commitment to Deliver Synthetic RNA Controls, now to Fight Delta Plus Variants of COVID-19

-- Latest Variants of Concern, AY.1 and AY.2 Controls Now Available for Development of Accurate Diagnostic Tests -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 14, 2021-- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of

Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON --(BUSINESS WIRE)--Sep. 13, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Adicet Bio, Inc.

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration Content Import Thu, 09/09/2021 - 09:56 Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration September 9, 2021 This release …

Twist Bioscience to Present at Baird 2021 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 8, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M.

Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit

Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit Content Import Tue, 08/10/2021 - 08:01 Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit August 10, 2021 This release is a backfill from a News Wire…

Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results

-- Revenue Growth of 65% over Fiscal 2020 Third Quarter -- -- Order Growth of 58% Year over Year -- -- Gross Margin of 40% for the Quarter -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 6, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through
Show more

Twist Bioscience Frequently Asked Questions

  • Who are Twist Bioscience key executives?

    Twist Bioscience's key executives are Emily Leproust, Jim Thorburn and Patrick Weiss.

  • How many employees does Twist Bioscience have?

    Twist Bioscience has 525 employees.

  • What is Twist Bioscience revenue?

    Latest Twist Bioscience annual revenue is $90.1 m.

  • What is Twist Bioscience revenue per employee?

    Latest Twist Bioscience revenue per employee is $171.6 k.

  • Who are Twist Bioscience competitors?

    Competitors of Twist Bioscience include Promega, Eurofins Genomics and Integrated DNA Technologies.

  • Where is Twist Bioscience headquarters?

    Twist Bioscience headquarters is located at 681 Gateway Blvd, South San Francisco.

  • Where are Twist Bioscience offices?

    Twist Bioscience has offices in South San Francisco, Carlsbad, San Francisco, Guangzhou Shi and in 2 other locations.

  • How many offices does Twist Bioscience have?

    Twist Bioscience has 6 offices.